Join FibroGen for the second part of the virtual KOL investor event series featuring Rahul Aggarwal, MD (University of California San Francisco), who will discuss the unmet need and evolving treatment landscape for prostate cancer, as well as the clinical development program for FG-3246* (also known as FOR46), a CD46 targeting antibody-drug conjugate (ADC) with first-in-class potential for the treatment of metastatic castration-resistant prostate cancer (mCRPC) expected to enter Phase 2 in 2024.

The event will additionally review data from the Phase 1b/2 study evaluating FG-3246 in combination with enzalutamide in mCRPC presented at ASCO 2024. The initiation of Phase 2 trial in mCRPC is expected in the second half of 2024.

A live question and answer session will follow the formal presentation.

*FG-3246 is an investigational drug and not approved for marketing by any regulatory authority.